Literature DB >> 9714779

Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.

K Loughney1, T R Hill, V A Florio, L Uher, G J Rosman, S L Wolda, B A Jones, M L Howard, L M McAllister-Lucas, W K Sonnenburg, S H Francis, J D Corbin, J A Beavo, K Ferguson.   

Abstract

Human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase (PDE5A) cDNAs were isolated. A 3.1-kb composite DNA sequence assembled from overlapping cDNAs encodes an 875-amino-acid protein with a predicted molecular mass of 100012 Da (PDE5A1). Extracts prepared from yeast expressing human PDE5A1 hydrolyzed cGMP. This activity was inhibited by the selective PDE5 inhibitors zaprinast and DMPPO. PDE5A mRNA is expressed in aortic smooth muscle cells, heart, placenta, skeletal muscle and pancreas and, to a much lesser extent, in brain, liver and lung. A 5'-splice variant, PDE5A2, encodes an 833-amino-acid protein with eight unique amino acids at the amino terminus. PDE5A maps to chromosome 4q 25-27.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714779     DOI: 10.1016/s0378-1119(98)00303-5

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  47 in total

1.  Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.

Authors:  K S Murthy
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

Authors:  Longhu Li; Husnain Kh Haider; Linlin Wang; Gang Lu; Muhammad Ashraf
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

4.  Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation.

Authors:  Tünde Tömöri; István Hajdú; László Barna; Zsolt Lorincz; Sándor Cseh; György Dormán
Journal:  Mol Divers       Date:  2011-09-27       Impact factor: 2.943

5.  A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors.

Authors:  Nermin S Ahmed; Bernard D Gary; Gary A Piazza; Heather N Tinsley; Stefan Laufer; Ashraf H Abadi
Journal:  Med Chem       Date:  2010-11       Impact factor: 2.745

Review 6.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

7.  Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Authors:  Alberto J Kaumann; Alejandro Galindo-Tovar; Elisa Escudero; María Luisa Vargas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-20       Impact factor: 3.000

8.  Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.

Authors:  M Bertolotto; E Trincia; R Zappetti; R Bernich; G Savoca; M A Cova
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

9.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.